Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity. Albeit cardiovascular outcomes generally improve, treatment with GLP-1 RAs is associated with increased heart rate, the mechanism of which is unclear. Methods and results: We employed a large animal model, the female landrace pig, and used multiple in vivo and ex vivo approaches including pharmacological challenges, electrophysiology, and high-resolution mass spectrometry to explore how GLP-1 elicits an increase in heart rate. In anaesthetized pigs, neither cervical vagotomy, adrenergic blockers (alpha, beta, or combined alpha-beta blockade), ganglionic blockade (hexamethonium), nor inhibition of hyperpolarization-activated cyclic nucleotide–gated (HCN) channels (ivabradine) abolished the marked chronotropic effect of GLP-1. GLP-1 administration to isolated perfused pig hearts also increased heart rate, which was abolished by GLP-1 receptor blockade. Electrophysiological characterization of GLP-1 effects in vivo and in isolated perfused hearts localized electrical modulation to the atria and conduction system. In isolated sinus nodes, GLP-1 administration shortened the action potential cycle length of pacemaker cells and shifted the site of earliest activation. The effect was independent of HCN blockade. Collectively, these data support a direct effect of GLP-1 on GLP-1 receptors within the heart. Consistently, single nucleus RNA sequencing showed GLP-1 receptor expression in porcine pacemaker cells. Quantitative phosphoproteomics analyses of sinus node samples revealed that GLP-1 administration leads to phosphorylation changes of calcium cycling proteins of the sarcoplasmic reticulum, known to regulate heart rate. Conclusion: GLP-1 has direct chronotropic effects on the heart mediated by GLP-1 receptors in pacemaker cells of the sinus node, inducing changes in action potential morphology and the leading pacemaker site through a calcium signalling response characterized by PKA-dependent phosphorylation of Ca2+ cycling proteins involved in pacemaking. Targeting the pacemaker calcium clock may be a strategy to lower heart rate in people treated with GLP-1 RAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · cited 1×
“The positive outcomes of the clinical trials have—under-standably—led to a lot of excitement, and current guidelines in cardiology 50 and diabetes 51 now recommend the use of GLP-1 RAs to reduce cardiovascular risk in high-risk patients with T2D.”
BackgroundIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 1×
“For instance in patients with heart failure with reduced ejection fraction, where heart rate is a risk factor, 31 its reduction improves clinical outcome 32,33 and guidelines accordingly recommend rate control with beta-blockers or ivabradine when necessary.”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 2×
“…with preserved ejection fraction and obesity found that treatment with semaglutide, a GLP-1 RA with marked weight loss effects, reduced body weight 55 and heart failure-related symptoms 10 and improved exercise function 55 in these patients, in addition to reducing major cardiovascular events.”
BackgroundSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“…14 with estimates exceeding 20% for heart rate increases of 10 b.p.m. 13 GLP-1 RA cardiovascular outcome trials 2–9 and head-to-head studies, 15–29 with a follow-up range of 0.5–5.4 years, have documented that GLP-1 RAs increase heart rate by 0.1–5.7 b.p.m., with an average increase of 2.4…”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“Specifically, the signature phosphorylation downstream of cAMP-induced protein kinase A (PKA) activation, phosphorylation of phospholamban on serine 16, is up-regulated ( Figure 7F and G ; Supplementary material online, Figure S9E ).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“47 In addition, the effect was evaluated in the absence or presence of the DDP-4 inhibitor Val-Pyr.”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“42 However, Wallner et al .”
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · cited 3×
“56 In line with the question of arrhythmia risk, a recent meta-analysis reviewed the association of GLP-1 RAs and incident arrhythmias.”
BackgroundKim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 1×
“The GLP-1 receptor was localized to the atria in rodents, 71 but in humans and monkeys, it was found by immunohistochemistry and ligand binding to be localized exclusively to the sinus node.”
BackgroundDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Spatially resolved multiomics of human cardiac niches
Kanemaru, K., Cranley, J., Muraro, D., Miranda, A. M. A., Ho, S. Y., Wilbrey-Clark, A., Patrick Pett, J., Polanski, K., Richardson, L., Litvinukova, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06311-1 · Cited by 425
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243 · cited 1×
“52,53 Additionally, GLP-1 treatment clearly modifies several cardiovascular risk factors, including body weight, blood pressure, plasma glucose concentrations, plasma LDL cholesterol, and triglycerides.”
BackgroundSelf-citationYamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Hozawa (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.019 · Cited by 136 · cited 1×
“13 A resting heart rate increase of 5 b.p.m. has been associated with a 17% increase in cardiovascular mortality, 14 with estimates exceeding 20% for heart rate increases of 10 b.p.m. 13 GLP-1 RA cardiovascular outcome trials 2–9 and head-to-head studies, 15–29 with a follow-up range of 0.5–5.4…”
BackgroundInfluentialKosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jon Jensen, T., Rasmussen, S., Erlang Marstrand, P., Petrie, M. C., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067505 · Cited by 104 · cited 2×
“10 Despite the reported cardiovascular benefits, the prescription of GLP-1 RA by cardiologists has so far remained low.”
BackgroundReappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1682 · Cited by 42 · cited 1×
“For instance in patients with heart failure with reduced ejection fraction, where heart rate is a risk factor, 31 its reduction improves clinical outcome 32,33 and guidelines accordingly recommend rate control with beta-blockers or ivabradine when necessary.”
BackgroundHuang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Research works printed but not linked: 36
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Dave, 2020, Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018, Diabetes Care, 43, 921, 10.2337/dc19-1943 · DOI · Paper page
- Marx, 2022, GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes, Circulation, 146, 1882, 10.1161/CIRCULATIONAHA.122.059595 · DOI · Paper page
- Perret-Guillaume, 2009, Heart rate as a risk factor for cardiovascular disease, Prog Cardiovasc Dis, 52, 6, 10.1016/j.pcad.2009.05.003 · DOI · Paper page
- Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- Pratley, 2018, Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinol, 6, 275, 10.1016/S2213-8587(18)30024-X · DOI · Paper page
- Bohm, 2010, Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial, Lancet, 376, 886, 10.1016/S0140-6736(10)61259-7 · DOI · Paper page
- Baggio, 2017, The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice, Mol Metab, 6, 1339, 10.1016/j.molmet.2017.08.010 · DOI · Paper page
- Griffioen, 2011, GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons, Cardiovasc Res, 89, 72, 10.1093/cvr/cvq271 · DOI · Paper page
- Ang, 2018, Modulation of cardiac ventricular excitability by GLP-1 (glucagon-like peptide-1), Circ Arrhythm Electrophysiol, 11, e006740, 10.1161/CIRCEP.118.006740 · DOI · Paper page
- Jøns, 2021, Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy, Life Sci, 282, 119815, 10.1016/j.lfs.2021.119815 · DOI
- Asmar, 2016, Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy, Am J Physiol Endocrinol Metab, 310, E744, 10.1152/ajpendo.00518.2015 · DOI · Paper page
- Clauss, 2019, Animal models of arrhythmia: classic electrophysiology to genetically modified large animals, Nat Rev Cardiol, 16, 457, 10.1038/s41569-019-0179-0 · DOI · Paper page
- van Opbergen, 2022, Exercise causes arrhythmogenic remodeling of intracellular calcium dynamics in plakophilin-2-deficient hearts, Circulation, 145, 1480, 10.1161/CIRCULATIONAHA.121.057757 · DOI · Paper page
- Vinogradova, 2006, High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells, Circ Res, 98, 505, 10.1161/01.RES.0000204575.94040.d1 · DOI · Paper page
- Lundby, 2013, In vivo phosphoproteomics analysis reveals the cardiac targets of beta-adrenergic receptor signaling, Sci Signal, 6, rs11, 10.1126/scisignal.2003506 · DOI · Paper page
- Lubberding, 2023, Cardiovascular endocrinology and metabolism, 365, 10.1016/B978-0-323-99991-5.00017-6 · DOI
- Daghlas, 2021, Genetic evidence for repurposing of GLP1R (glucagon-like peptide-1 receptor) agonists to prevent heart failure, J Am Heart Assoc, 10, e020331, 10.1161/JAHA.120.020331 · DOI
- Kumarathurai, 2016, Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study, Cardiovasc Diabetol, 15, 105, 10.1186/s12933-016-0425-2 · DOI · Paper page
- Monami, 2017, Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials, J Endocrinol Invest, 40, 1251, 10.1007/s40618-017-0698-7 · DOI
- Wu, 2022, Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials, Diabetol Metab Syndr, 14, 195, 10.1186/s13098-022-00970-2 · DOI
- Axelsen, 2012, Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts, Br J Pharmacol, 165, 2736, 10.1111/j.1476-5381.2011.01714.x · DOI · Paper page
- Wettergren, 1998, Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow, Am J Physiol, 275, G984
- Plamboeck, 2013, The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty, Am J Physiol Gastrointest Liver Physiol, 304, G1117, 10.1152/ajpgi.00035.2013 · DOI · Paper page
- Tougaard, 2020, Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events, Scand Cardiovasc J, 54, 294, 10.1080/14017431.2020.1751873 · DOI
- Serre, 1998, Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3’,5'-monophosphate levels and beta-cell glucose competence, Endocrinology, 139, 4448, 10.1210/endo.139.11.6295 · DOI · Paper page
- MacDonald, 2020, Neurohumoral control of sinoatrial node activity and heart rate: insight from experimental models and findings from humans, Front Physiol, 11, 170, 10.3389/fphys.2020.00170 · DOI
- Brennan, 2020, Evidence of superior and inferior sinoatrial nodes in the mammalian heart, JACC Clin Electrophysiol, 6, 1827, 10.1016/j.jacep.2020.09.012 · DOI
- Monfredi, 2010, The anatomy and physiology of the sinoatrial node–a contemporary review, Pacing Clin Electrophysiol, 33, 1392, 10.1111/j.1540-8159.2010.02838.x · DOI · Paper page
- Dalsgaard, 2018, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons, Diabetes Obes Metab, 20, 508, 10.1111/dom.13128 · DOI · Paper page
- Wallner, 2015, Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium, J Mol Cell Cardiol, 89, 365, 10.1016/j.yjmcc.2015.09.018 · DOI
- Linscheid, 2019, Quantitative proteomics and single-nucleus transcriptomics of the sinus node elucidates the foundation of cardiac pacemaking, Nat Commun, 10, 2889, 10.1038/s41467-019-10709-9 · DOI
- Maltsev, 2008, Dynamic interactions of an intracellular Ca2+ clock and membrane ion channel clock underlie robust initiation and regulation of cardiac pacemaker function, Cardiovasc Res, 77, 274, 10.1093/cvr/cvm058 · DOI
- Wainger, 2001, Molecular mechanism of cAMP modulation of HCN pacemaker channels, Nature, 411, 805, 10.1038/35081088 · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“A common fi nding amongst all GLP-1 trials was that of increased heart rate attributed to a direct e ff ect on the pacemaker cells within the sinus node of the heart [185]. the development of pancreatitis [159].”
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“…hearts or isolated sinoatrial node tissues, Lubberd-ing et al. documented that, independently of autonomic nervous system blockade or the presence of ivabradine, GLP-1 increases spontaneous action potential firing and diastolic depolarization slope in isolated pig sinoatrial node preparations [54].”
Metadata
- Authors
- Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., Toräng, S., Larsen, S. A., Nissen, A., Petersen, L. G., Bilir, S. E., Bentzen, B. H., Rosenkilde, M. M., Hartmann, B., Lilleør, T. N. B., Qazi, S., Møller, C. H., Tfelt-Hansen, J., Sattler, S. M., Jespersen, T., Holst, J. J., & Lundby, A.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-06-04
- Volume
- 120
- Issue
- 12
- Pages
- 1427-1441
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W4399327314
- Cited by
- 84
- References
- 40
- FWCI
- 22.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.